吡拉西坦联合尼莫地平对脑梗塞后血管性痴呆的临床疗效分析

Clinical Effect of Piracetam Combined with Nimodipine on Vascular De-mentia after Cerebral Infarction

目的探讨利用吡拉西坦联合尼莫地平治疗脑梗塞后血管性痴呆所得到临床效果。方法整群选择2014年2月—2015年3月该院曾收治的脑梗塞后血管性痴呆患者110例,以随机分组方式分为观察组与对照组,对照组中患者以尼莫地平进行治疗,观察组患者选择吡拉西坦联合尼莫地平方法治疗。结果观察组中患者所达到临床有效率为90.9%,对照组中患者所得到临床有效率仅为72.7%;观察组患者MMSE评分及ADL评分治疗前后改善情况比对照组优秀;对照组中患者不良反应发生者有5例,观察组中有6例患者出现不良反应,两组患者之间在临床有效率、MMSE评分及ADL评分改善情况方面差异有统计学意义,不良反应差异无统计学意义(P>0.05)。结论对脑梗塞后血管性痴呆选择吡拉西坦联合尼莫地平进行治疗临床有效率比较高,可改善患者临床症状,提高MMSE评分及ADL评分,并且不会增加不良反应。

Objective To investigate the clinical effect of piracetam combined with nimodipine vascular dementia after cerebral infarction by. Methods From 2014 February to March 2015, our hospital has treated 110 cases of patients with vascular dementia after cerebral infarction, with grouping randomly divided into observation group and control group, patients in the control group treated with nim horizon, the observation group of patients choose pyrazole raschig combined therapy with nim horizon method. Results The patients achieved clinical effective rate was 90.9% in observation group, patients in the control group by clinical efficiency is only 72.7%; Observation group of patients with MMSE score and ADL scores before and after treatment to improve the situation better than control group; Control group of patients with adverse reactions occurred in 5 cases, 6 patients in observation group adverse reactions between the two groups of patients in the clinical efficient and MMSE scores and ADL scores improved, there is a statistically significant adverse reaction there is no statistical difference. Conclusion Vascular dementia after cerebral infarction of selecting pyrazole raschig temple joint nim horizon for clinical effective rate is higher, can improve clinical symptoms, improve the MMSE scores and ADL scores, and will not increase adverse reactions.